MacroGenics reported $107.23M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Daiichi Sankyo JPY 882.78B 117.08B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
Geron USD 74.25M 3.92M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
J&J USD 55.46B 562M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 107.23M 1.58M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Xencor USD 76.27M 5.6M Sep/2026